Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

378
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
378
Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

384
 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
384
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

343
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
343
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

415
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
415
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

438
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
438

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking ethical reflexivity and oversight in health research through an ecosystem approach: A workshop report.

Research ethics·2026
Same author

A Method for Adapting Euglena gracilis to Cassava-Based Substrates for Heterotrophic Cultivation.

Journal of visualized experiments : JoVE·2026
Same author

Shifting power: co-developing a framework for equity in healthcare.

BMC health services research·2026
Same author

Digital health tools and point solutions-pitfalls in population health program measurement.

Frontiers in digital health·2026
Same author

Ankle brachial index not a reliable tool for risk assessment in people with HIV.

HIV medicine·2026
Same author

Building Canada's Health Information Ecosystem Through Equitable Approaches to Public, Patient, and Community Engagement.

Healthcare management forum·2026

Related Experiment Video

Updated: Feb 3, 2026

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease
08:38

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease

Published on: August 26, 2017

7.6K

Gene therapy for peripheral arterial disease.

Rachel Forster1, Aaron Liew, Vish Bhattacharya

  • 1Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK, EH8 9AG.

The Cochrane Database of Systematic Reviews
|November 1, 2018
PubMed
Summary

Gene therapy for peripheral arterial disease (PAD) shows no clear benefits for survival or amputation rates. While it may improve ulcer healing, more research is needed to confirm its effectiveness and impact on quality of life.

More Related Videos

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

2.0K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.4K

Related Experiment Videos

Last Updated: Feb 3, 2026

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease
08:38

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease

Published on: August 26, 2017

7.6K
Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

2.0K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.4K

Area of Science:

  • Vascular Medicine
  • Regenerative Medicine
  • Clinical Trials

Background:

  • Peripheral arterial disease (PAD) is a growing vascular condition, particularly in aging populations and individuals with diabetes.
  • PAD can lead to severe limb pain, ulceration, and even limb loss (critical limb ischaemia).
  • Current treatments for PAD include medications and surgical interventions, but many patients are unresponsive or unsuitable for these options.

Purpose of the Study:

  • To assess the efficacy and safety of gene therapy as a treatment for symptomatic peripheral arterial disease (PAD).

Main Methods:

  • A systematic review and meta-analysis of randomized and quasi-randomized controlled trials.
  • Searched multiple databases including Cochrane CENTRAL, MEDLINE, Embase, CINAHL, and AMED up to November 2017.
  • Included 17 studies with 1988 participants evaluating various gene therapies for PAD.

Main Results:

  • Moderate-quality evidence indicates no significant differences in amputation-free survival, major amputation rates, or all-cause mortality between gene therapy and control groups.
  • Low-quality evidence suggests a potential improvement in complete ulcer healing with gene therapy (OR 2.16, 95% CI 1.02 to 4.59).
  • Data on quality of life, ankle brachial index, and symptom scores were insufficient for definitive conclusions due to heterogeneity and low-quality evidence.

Conclusions:

  • Gene therapy does not demonstrate clear benefits for major adverse cardiovascular events or limb outcomes in PAD patients.
  • Further research with standardized reporting is required to confirm the potential benefits of gene therapy for ulcer healing and other patient-reported outcomes.
  • High-quality, standardized trials are needed to evaluate the long-term efficacy and impact of gene therapy on quality of life in PAD.